Wave Life Sciences (WVE) Shares Plunge 30% Even as Company Calls Obesity Trial Results Positive

TLDR

• Wave Life Sciences shares dropped 30% on Thursday following the release of interim Phase 1 data from its INLIGHT trial for obesity.
• A single 240mg dose of WVE-007 led to a 14% reduction in visceral fat, adjusted for placebo, over a six-month period.
• Participants in the trial had a lower average BMI (32) compared to typical obesity studies, making direct comparisons with competing treatments difficult.
• Jefferies reaffirmed its Buy rating and $28 price target for WVE prior to the data announcement.
• Wave intends to commence Phase 2a of INLIGHT in Q2 2026, focusing on patients with higher BMIs and co-existing conditions.

---

(SeaPRwire) –   Wave Life Sciences unveiled interim Phase 1 data from its INLIGHT trial on Thursday, a release that failed to impress the market. The company’s stock plummeted 30% that day, despite the results being characterized as positive by Wave.

Wave Life Sciences Ltd., WVE

The disclosed data pertained to WVE-007, a therapeutic agent for obesity. A solitary 240mg dose resulted in a 14% placebo-adjusted decrease in visceral fat over half a year among participants whose average BMI was 32 kg/m².

The firm also reported a 16.5% improvement in the visceral fat-to-muscle ratio from baseline. Lean mass saw an increase of 2.4%, waist circumference decreased by 3.3%, and body weight fell by 0.9% on a placebo-adjusted basis.

WVE-007 demonstrated good tolerability at doses up to 600mg. No participants discontinued treatment, and no severe adverse events were reported. Reductions in serum Activin E were sustained for at least seven months, suggesting the potential for once or twice-yearly administration.

The main concern? The mean BMI in this group was 32 — significantly lower than the typical 37 observed in Phase 2 and 3 obesity trials. This discrepancy complicates direct comparisons with other developing medications.

Wave drew a comparison between WVE-007’s visceral fat outcomes and those of weekly semaglutide from a separate Phase 2 trial. However, that semaglutide study involved patients with higher BMIs, which made the comparison questionable.

Investors likely weighed these limitations against the backdrop of a highly competitive obesity drug market, currently dominated by pharmaceutical giants Novo Nordisk and Eli Lilly.

Phase 2a On The Horizon

Wave plans to initiate the Phase 2a segment of the INLIGHT study in the second quarter of 2026. This upcoming study will recruit patients with a BMI ranging from 35–50 who also have comorbidities — a more representative population for obesity trials.

The company anticipates that the cohort with higher BMIs will exhibit more pronounced improvements in body composition and weight loss. Data from this study will guide Wave’s development strategy across various conditions, including obesity, MASH, type 2 diabetes, and cardiovascular disease.

Just one day prior to the data release, Jefferies had reiterated its Buy rating and $28 price target for WVE, highlighting the RNA editing methodology and the INHBE program as key growth drivers.

Analyst Roger Song pointed out potential benefits of Wave’s platform, such as the absence of off-target editing, a cleaner safety profile, and lasting effects with convenient infrequent dosing.

Additional Pipeline Updates

In other news, Wave fully reacquired the rights to WVE-006 from GSK. The company is scheduled to present a poster at ADA and expects to provide updates on the 400mg multiple ascending dose and 600mg single ascending dose cohorts in May.

Mizuho increased its price target for WVE to $27 from $22 earlier this year, maintaining an Outperform rating after Wave assumed complete ownership of WVE-006.

Wave also recently announced its Q4 and full-year 2025 earnings, noting financial strain due to the conclusion of a significant collaboration. While revenue surpassed projections, earnings per share fell short of expectations.

According to InvestingPro data, the company possesses more cash than debt on its balance sheet.

Results from the RestorAATion-2 trial of WVE-006 are slated for presentation at the American Thoracic Society International Conference in 2026, covering the 400mg multidose and 600mg single-dose groups.